What this domain asks
Risk that complaints, adverse-event indicators, product-quality complaints, vigilance, field actions, recalls, post-market surveillance, and regulatory reporting are delayed or fragmented across quality, safety, medical, regulatory, and commercial systems.
The domain should retain its own evidence, decision owner, materiality criteria, exception path, and consequence even when it shares organization identity, workflow, or technology with adjacent domains. Aggregation can support oversight; it should not erase the evidence behind different risks or operating outcomes.
Buyer questions
- How are intake, duplicate detection, product identification, reportability assessment, investigation, and response divided across systems and teams?
- Can complaint records connect to batches, devices, suppliers, deviations, CAPA, risk files, registrations, labels, and prior events?
- Which regulatory reports and authority exchanges are native, integrated, or handled in a separate safety or device-reporting system?
- How are clocks, jurisdictions, seriousness, expectedness, malfunctions, trend thresholds, and escalation controlled?
- Can the system preserve human decisions and source evidence when automation assists classification or narrative preparation?
- How are field actions, recalls, corrections, customer communications, and effectiveness checks coordinated and evidenced?
Mapped workflows
Quality Events And Deviations
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for quality events and deviations within this domain.
CAPA
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for CAPA within this domain.
Change Control
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for change control within this domain.
Complaints And Post-Market Quality
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for complaints and post-market quality within this domain.
Quality Risk Management
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for quality risk management within this domain.
Design Controls And Product Traceability
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for design controls and product traceability within this domain.
Regulatory Product And Registration Data
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for regulatory product and registration data within this domain.
Regulatory Activity And Commitment Tracking
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for regulatory activity and commitment tracking within this domain.
Labeling And Structured Product Data
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for labeling and structured product data within this domain.
Health-Authority Correspondence
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for health-authority correspondence within this domain.
Analytics And Management Review
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for analytics and management review within this domain.
Authority context
FDA QMSR
The QMSR amends FDA's device current good manufacturing practice requirements in 21 CFR Part 820 and incorporates ISO 13485:2016 by reference, while retaining FDA-specific statutory and regulatory requirements. FDA began using a new device inspection process when the rule became effective.
FDA drug CGMP
Parts 210 and 211 establish current good manufacturing practice requirements for drug manufacture, processing, packing, and holding, including organization, facilities, equipment, components, production controls, laboratory controls, records, reports, returned products, and complaints.
ISO 13485:2016
ISO 13485 specifies quality-management-system requirements for organizations involved in one or more stages of the medical-device lifecycle and emphasizes regulatory requirements, risk-based processes, supplier control, documentation, and product realization.
ICH Q10
ICH Q10 describes a pharmaceutical quality-system model across development and commercial manufacturing, including management responsibilities, process and product monitoring, CAPA, change management, management review, knowledge management, and quality risk management.
EU MDR
The MDR establishes rules for placing medical devices on the EU market and covers economic operators, conformity assessment, quality systems, clinical evidence, technical documentation, UDI, registration, vigilance, post-market surveillance, and market surveillance.
EU IVDR
The IVDR establishes rules for in vitro diagnostic devices, including classification, conformity assessment, quality systems, performance evidence, technical documentation, UDI, registration, vigilance, post-market surveillance, and performance studies.
Relevant operating models
- Enterprise Life-Sciences EQMS
- Growth-Stage Life-Sciences EQMS
- Medical-Device Quality And Product-Lifecycle Platform
- Configurable QMS With Life-Sciences Offering
- Integrated Quality And Regulatory Platform
- Enterprise Regulatory Information Management Suite
- Medical-Device Regulatory Information Management
Evidence boundary
RegQuality Review is not a regulator, certification body, law firm, or validation authority. Its records support research and decision review; they do not establish compliance for an organization, system, release, configuration, or intended use. A provider's documented capability can identify a research candidate but cannot establish buyer-specific adequacy for this domain.